Fam-trastuzumab deruxtecan-NXKI

52% of BriaCell’s most-recent 25-patient cohort* have surpassed the one-year survival milestone, exceeding current standard of care in similar patients11 patients remain alive as of recent contact, including one patient at 38.3 months and another at 30.3 months Survival benefit observed in heavily pre-treated patients, including those who failed treatment with checkpoint inhibitors (CPIs) and antibody-drug conjugates (ADCs) PHILADELPHIA and VANCOUVER, British Columbia, July 08, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, has reported updated survival data from its ongoing Phase 2 clinical study of Bria-IMT in patients with metastatic breast cancer (MBC). BriaCell’s most recent Phase 2 study cohort of 25 patients* achieved a 52% one-year survival rate (i.e. 52% of patients remained alive at least one year after starting on the study).11 of these patients remain alive as of most recent contact, including one patient at 38.3 months and another at 30.3 months (see Table 1).Survival rate exceeds the survival expectations with the current standard of care therapies in similar patient populations (see Table 2).Notably, many patients had very advanced metastatic breast cancer, having already failed multiple prior lines of therapy including check point inhibitors (CPIs) and antibody-drug conjugates (ADCs) such as TRODELVY® - (sacituzumab govitecan-hziy) and ENHERTU® (fam-trastuzumab - deruxtecan-nxki).No treatment discontinuations attributed to Bria-IMT have been reported. Table 1: Select Long-Term RespondersPatientMonths SurvivalAgePrior RegimensCycles of Bria-IMT01-00938.37451307-00130.3557; including ENHERTU811-01821.66682811-01920.0639; including TRODELVY616-00319.4805; including ENHERTU8 “BriaCell’s Phase 2 data indicate a robust survival signal and a well-tolerated profile,” stated Adam M. Brufsky, MD, PhD, FACP, Professor of Medicine at the University of Pittsburgh School of Medicine and Medical Director of the Magee-Women's Cancer Program. “These results reinforce BriaCell’s potential to improve survival and tolerability for late-stage patients.” “Many patients with metastatic breast cancer unfortunately have disease progression despite treatment with CPIs and ADCs,” added Aditya Bardia, MD, MPH, FASCO, a leading breast cancer expert. “BriaCell’s survival data in single arm Phase 2 trial highlights the potential activity of Bria-IMT in combination with CPIs and is subject to ongoing investigation in a Phase 3 randomized clinical trial in MBC.” Table 2: Comparable Analysis of One-Year Survival ReferenceBreast Cancer TypeMedian prior lines of therapyPercent Survival at 1 yearBria-IMT plus CPIAll types:61% HR+33% TNBC6% HER2+652%*Cortes et al.1All types: 57% HR+ 18-19% TNBC18-20% HER2+4~38-40%Kazmi et al.2 All types: 51-52% HR+ 25-29% TNBC9-24% HER2+230-38%Bardia et al. (TPC arm)3TNBC2-3~23%Rugo et al (TPC arm)4HR+ HER2-247% * 25 patients treated with the Phase 3 formulation since 2022 Cortes J, et al. Annals of Oncology 2018Kazmi S, et al. Breast Cancer Res Treat. 2020Bardia A, et al. J Clin Oncol. 2024Rugo HS, et al. The Lancet. 2023 Abbreviations: HR+: hormone receptor-positiveTNBC: Triple-negative breast cancer (lacks or has low levels of the estrogen receptor, progesterone receptor, and human epidermal growth factor 2 (HER2))HER2+: Human epidermal growth factor receptor 2 positiveHR+ HER2-: hormone receptor-positive and human epidermal growth factor receptor 2 negativeTPC: Treatment of Physicians Choice BriaCell’s Phase 2 study enrolled 54 heavily pre-treated metastatic breast cancer patients (median number of prior treatments = 6) who received the Bria-IMT regimen plus checkpoint inhibitor. Of these 54 patients, 37 were treated with the formulation currently being used in BriaCell’s ongoing pivotal Phase 3 study in metastatic breast cancer (listed on ClinicalTrials.gov as NCT06072612). Final median overall survival calculation for the Phase 2 study is pending for some sub populations as many patients remain alive. No Bria-IMT-related discontinuations have been reported to date. About BriaCell Therapeutics Corp. BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at https://briacell.com/. Safe Harbor This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements, including statements about: BriaCell’s potential to improve survival and tolerability for late-stage metastatic breast cancer patients; the impact of Bria-IMT™ on patients with metastatic breast cancer; and BriaCell’s further clinical development of Bria-IMT™ are based on BriaCell’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading “Risks and Uncertainties” in the Company’s most recent Management’s Discussion and Analysis, under the heading “Risk Factors” in the Company’s most recent Annual Information Form, and under “Risks and Uncertainties” in the Company’s other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company’s profiles on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law. Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release. Contact Information Company Contact: William V. Williams, MDPresident & CEO 1-888-485-6340 info@briacell.com Investor Relations Contact: investors@briacell.com

AstraZeneca CEO Pascal Soriot is considering a move of the company's primary stock listing from London to the U.S., according to British news outlet The Times. Just days after President Donald Trump was elected in November, AstraZeneca unveiled a plan to invest an additional $2 billion, more than doubling its outlay to grow its manufacturing and R&D presence in the United States through 2026.Eight months later, AZ CEO Pascal Soriot is reportedly plotting a shift of the company’s primary stock listing from London to the U.S., according to The Times. The British news outlet cites multiple unnamed sources, including one who added that Soriot has even discussed basing AZ’s business in the U.S.The 66-year-old Soriot, who has headed up AZ for 13 years and is one of the most powerful voices in the industry, has often jousted with the U.K. government, frustrated with how its drug regulators handled approvals and pricing. Less than a year ago, Soriot was critical of England’s National Institute for Health and Care Excellence (NICE), when it rejected AZ’s Daiichi Sankyo-partnered cancer blockbuster Enhertu, denying access to the drug in HER2-low breast cancer. Losing AZ would be a major blow to the London Stock Exchange. With a market cap of $219 billion, the drugmaker is the second-largest company in the U.K., ranking just behind chemical giant Linde and ahead of firms such as HSBC, Shell, Unilever and Rolls-Royce.The rumors come as the threat of Trump-led tariffs looms over the pharmaceutical industry. Three months ago, CEOs from 32 drugmakers signed off on a letter to European Commission President Ursula von der Leyen demanding more favorable drug policies and threatening an investment exodus to the U.S. The European Federation of Pharmaceutical Industries and Associations (EFPIA) warned von der Leyen that unless Europe delivers “rapid, radical policy change,” pharmaceutical R&D and manufacturing is “increasingly likely to be directed towards the U.S. The EPPIA estimated that more than $100 billion in investment could leave the EU.Like many of its Big Pharma peers, AZ already has strong financial ties to the U.S. Of its $50.9 billion product sales in 2024, $21.7 billion came in the U.S., compared to $10.8 billion in Europe.